Literature DB >> 26108002

Occult HBV infection status among chronic hepatitis C and hemodialysis patients in Northeastern Egypt: regional and national overview.

Mohamed Mandour1, Nader Nemr2, Atef Shehata3, Rania Kishk3, Dahlia Badran4, Nashaat Hawass2.   

Abstract

INTRODUCTION: Occult hepatitis B infection (OBI) is considered to be one of the major risks for patients suffering from end-stage renal disease (ESRD) on regular hemodialysis (HD) and patients with chronic hepatitis C virus (HCV) infection. This study compared the prevalence of OBI among these two high-risk groups in the Suez Canal region, Northeastern Egypt, to obtain a better national overview of the magnitude of OBI in this region.
METHODS: Serum samples were collected from 165 HD patients and 210 chronic HCV-infected patients. Anti-HCV antibody, hepatitis B surface antigen (HBsAg), total hepatitis B core (anti-HBc) antibody, and hepatitis B surface antibody (anti-HBs) were detected by enzyme-linked immunosorbent assay (ELISA). HCV RNA was detected using a quantitative real-time RT-PCR assay, and HBV was detected using a nested PCR.
RESULTS: All patients were negative for HBsAg. A total of 49.1% and 25.2% of the patients in the HD and HCV groups, respectively, were anti-HBc-positive. In addition, more anti-HBs-positive patients were detected in the HD group compared to the HCV group (52.1% and 11.4%, respectively). Three cases were positive for HBV DNA in the HD group, while eighteen positive cases were detected in the HCV group. Both study groups showed significant differences in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level as well as anti-HBc, anti-HBs and HBV-DNA positivity.
CONCLUSIONS: OBI was more prevalent among chronic HCV patients than HD patients in the Suez Canal region, Egypt, with rates of 8.5% and 1.8%, respectively. However, more precise assessment of this infection requires regular patient follow-up using HBV DNA detection methods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26108002     DOI: 10.1590/0037-8682-0037-2015

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  6 in total

1.  Occult Hepatitis B Infection among Hemodialysis in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region.

Authors:  Narges Eslami; Vahdat Poortahmasebi; Javid Sadeghi; Reza Ghotaslou; Bahram Niknafs; Hossein Bannazadeh Baghi; Mahin Ahangar Oskouee
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-06-28       Impact factor: 2.585

Review 2.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

3.  The prevalence of occult HBV infection in immunized children with HBsAg-positive parents: a hospital-based analysis.

Authors:  Shurui Zhuge; Congcong Ge; Yuting Yang; Yuxia Cui; Xiaomei Yue; Zhenzhen Zhang; Hongmei Xu; Ailong Huang; Yao Zhao
Journal:  Hepatol Int       Date:  2020-05-29       Impact factor: 6.047

4.  Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: A retrospective cohort study.

Authors:  Mohit Bhatia; Ekta Gupta; Manish C Choudhary; Ankur Jindal; Shiv Kumar Sarin
Journal:  J Lab Physicians       Date:  2018 Jul-Sep

5.  Occult Hepatitis B Virus Infection in Maintenance Hemodialysis Patients: Prevalence and Mutations in "a" Determinant.

Authors:  Yun Tang; Xiangqin Liu; Xiangheng Lu; Qiang He; Guisen Li; Yang Zou
Journal:  Int J Med Sci       Date:  2020-08-25       Impact factor: 3.738

6.  Immunomodulatory Efficacy-Mediated Anti-HCV and Anti-HBV Potential of Kefir Grains; Unveiling the In Vitro Antibacterial, Antifungal, and Wound Healing Activities.

Authors:  Sawsan Abd Ellatif; Elsayed S Abdel Razik; Marwa M Abu-Serie; Ahmed Mahfouz; Abdullah F Shater; Fayez M Saleh; Mohamed M Hassan; Walaa F Alsanie; Abdullah Altalhi; Ghadir E Daigham; Amira Y Mahfouz
Journal:  Molecules       Date:  2022-03-21       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.